Discover

Back to filter

Related topics

Intoducing cellenONE: The revolutionary Single Cell isolator

Cellenion

May 25, 2022

A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Why use Cytek Aurora?

Cytek Biosciences

May 4, 2022

A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Introducing IsoPlexis Single-Cell Natural Killer Panel

IsoPlexis

Mar 4, 2022

Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...

Enhanced small particle detection on CytekAurora and Northern Lights

Cytek Biosciences

Mar 2, 2022

Aurora system with ESP option, can  fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...

Quantitative 3D Optical Imaging for Lago

Spectral Instruments Imaging

Feb 21, 2022

Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...

Molecular imaging study design basics

Spectral Instruments Imaging

Jan 31, 2022

By combining study design, study management, and image analytics in all major imaging modalities, BioLaurus has...

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 29, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Accelerating AML Research Through Single-cell Multi-omics- integrate seamlessly into existing NGS

Mission Bio

Nov 25, 2021

Dr. Linde Miles Memorial Sloan Kettering Cancer Center about her research, use of the Tapestri as a single-cell...

Show all topics (10)

MRI used to determine role of artificial sweeteners in pancreatic cancer disease progression

Jun 13, 2017

Pancreatic cancer has a remarkably high mortality rate, primarily due to late detection of the disease (Siegel et al. 2016). Therefore, efforts to reduce the incidence of pancreatic cancer may provide significant benefit in people at risk of developing the disease. Obese and diabetic individuals are known to have an increased risk of pancreatic cancer (Bardeesy et al. 2002).
Therefore, this study sought to determine whether aspartame or stevia, two commonly used artificial sweeteners, provide benefit in mice with pancreatic cancer. Lead author Dr. James Dooley and colleagues at the University of Leuven in Belgium published their paper entitled, “No Effect of Dietary Aspartame or Stevia on Pancreatic Acinar Carcinoma Development, Growth, or Induced Mortality in a Murine Model,” in Frontiers of Oncology in February of 2017.
The role of artificial sweeteners in cancer risk remains controversial (Tandel 2011), with some studies proposing anti-tumor effects while others purport carcinogenic properties of these chemicals. “With strong links to diabetes, glucose consumption and obesity, pancreatic cancer remains one of the strongest candidates to detect an oncogenic role, either promoting or suppressive, of artificial sweeteners,” the authors begin.
In order to test the potential role of these artificial sweeteners in pancreatic cancer disease progression, the authors allowed mice to drink water with or without aspartame or stevia present. The researchers used a Bruker Biospin 9.4 T Biospec small animal MR scanner to perform magnetic resonance imaging (MRI) in order to locate tumors in the mice and follow their progression over time.

Read more

Scientific paper
Application

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Bruker’s easy-to-use and cryogen-free high-performance compact MRI desktop system brings MRI within everyone’s reach

show detail

Multi-purpose high field MRI/MRS research systems, designed for the preclinical imaging and molecular MRI

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey